US General Anesthesia Drugs Market Analysis and Forecast to 2031: By Administration (Inhalational, and Intravenous), End-User (Hospitals, and Ambulatory Surgery Centers), and Company Type (Tier1 Pharmaceutical Companies, Tier2 Pharmaceutical Companies, Tier3 Pharmaceutical Companies)

US General Anesthesia Drugs are a class of drugs used to induce anesthesia. They are typically divided into three categories: general anesthetics, which induce anesthesia; neuromuscular blocking agents, which paralyze the muscles; and sedatives, which relax the patient.

Key Trends

Some of the key trends in US General Anesthesia Drugs technology include the development of more targeted and personalized drugs, the use of artificial intelligence to help identify new drug targets, and the use of 3D printing to create customized drugs.

There is also a trend towards using more natural substances, such as CBD, for general anesthesia.

Key Drivers

Some of the key drivers of the US General Anesthesia Drugs market include the increasing number of surgical procedures, the rising number of ambulatory surgical centers, the growing geriatric population, and the increasing prevalence of chronic diseases.

Restraints & Challenges

One of the key restraints in the US General Anesthesia Drugs market is the lack of awareness among patients and physicians about the availability of newer, safer and more effective drugs.

Another key restraint is the stringent regulations governing the approval and marketing of general anesthesia drugs in the US. This has made it difficult for new players to enter the market and compete with the established players.

Market Segments

The US anesthesia drugs market is segmented by route of administration, company type, and end-user. By administration, the market is classified into inhalational, and intravenous. On the basis of end-user, it is bifurcated into hospitals, and ambulatory surgery centers. Based on company type, it is divided into tier1 pharmaceutical companies, tier2 pharmaceutical companies, tier3 pharmaceutical companies.

Key Players

The US anesthesia drugs market includes players such as Baxter International, Pfizer, Bayer AG, AstraZeneca Plc, Sanofi, Akorn, Apotex, Gilead Sciences, Abbott Laboratories, Heritage Pharmaceuticals, and others.

Why GIS?

Table of Contents

Chapter 1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Methodologies
1.4. Market Estimation Techniques

Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market

Chapter 3. US General Anesthesia Drugs Market Outlook
3.1. US General Anesthesia Drugs Market Segmentation
3.2. Market Dynamics
3.2.1. Market Drivers Driver 1 Driver 2 Driver 3
3.2.2. Market Restraints Restraint 1 Restraint 2
3.2.3. Market Opportunities Opportunity 1 Opportunity 2
3.3. Porter’s Five Forces Analysis
3.3.1. Threat of New Entrants
3.3.2. Threat of Substitutes
3.3.3. Bargaining Power of Buyers
3.3.4. Bargaining Power of Supplier
3.3.5. Competitive Rivalry
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.5.1. Raw Material Suppliers
3.5.2. Manufacturers
3.5.3. Wholesalers and/or Retailers
3.6. Impact of the Russia and Ukraine War on the Global US General Anesthesia Drugs Market

Chapter 4. Economic Impact of COVID-19
4.1. Overall Impact of COVID-19
4.2. Impact of COVID On the Global US General Anesthesia Drugs Market
4.3. Economic Impact Analysis

Chapter 5. US General Anesthesia Drugs Market by Administration
5.1. Market Overview
5.2. Inhalational
5.2.1. Market Size and Forecast, 2021-2031 ($Million)
5.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
5.3. Intravenous
5.3.1. Market Size and Forecast, 2021-2031 ($Million)
5.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 6. US General Anesthesia Drugs Market by Company Type
6.1. Market Overview
6.2. Tier1 Pharmaceutical Companies
6.2.1. Market Size and Forecast, 2021-2031 ($Million)
6.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.3. Tier2 Pharmaceutical Companies
6.3.1. Market Size and Forecast, 2021-2031 ($Million)
6.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
6.4. Tier3 Pharmaceutical Companies
6.4.1. Market Size and Forecast, 2021-2031 ($Million)
6.4.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 7. US General Anesthesia Drugs Market by End-User
7.1. Market Overview
7.2. Hospitals
7.2.1. Market Size and Forecast, 2021-2031 ($Million)
7.2.2. Market Size and Forecast, by Region, 2021-2031 ($Million)
7.3. Ambulatory Surgery Centers
7.3.1. Market Size and Forecast, 2021-2031 ($Million)
7.3.2. Market Size and Forecast, by Region, 2021-2031 ($Million)

Chapter 8. Competitive Landscape
8.1. Market Overview
8.2. Market Share Analysis/Key Player Positioning
8.3. Developmental Strategy Benchmarking
8.3.1. New Product Development
8.3.2. Product Launches
8.3.3. Business Expansions
8.3.4. Partnerships, Joint Ventures, and Collaborations
8.3.5. Mergers and Acquisitions

Chapter 9. Company Profiles
10.1. Baxter International
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Offerings
10.1.4. Key Strategic Initiatives
10.1.5. SWOT Analysis
10.2. Pfizer
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product Offerings
10.2.4. Key Strategic Initiatives
10.2.5. SWOT Analysis
10.3. Bayer AG
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product Offerings
10.3.4. Key Strategic Initiatives
10.3.5. SWOT Analysis
10.4. AstraZeneca Plc
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product Offerings
10.4.4. Key Strategic Initiatives
10.4.5. SWOT Analysis
10.5. Sanofi
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product Offerings
10.5.4. Key Strategic Initiatives
10.5.5. SWOT Analysis
10.6. Akorn
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product Offerings
10.6.4. Key Strategic Initiatives
10.6.5. SWOT Analysis
10.7. Apotex
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product Offerings
10.7.4. Key Strategic Initiatives
10.7.5. SWOT Analysis
10.8. Gilead Sciences
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product Offerings
10.8.4. Key Strategic Initiatives
10.8.5. SWOT Analysis
10.9. Abbott Laboratories
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product Offerings
10.9.4. Key Strategic Initiatives
10.9.5. SWOT Analysis
10.10. Heritage Pharmaceuticals
10.10.1. Company Snapshot
10.10.2. Financial Performance
10.10.3. Product Offerings
10.10.4. Key Strategic Initiatives
10.10.5. SWOT Analysis

*The list of company is subject to change during the final compilation of the report


Key Players
  • Baxter International
  • Pfizer
  • Bayer AG
  • AstraZeneca Plc
  • Sanofi
  • Akorn
  • Apotex
  • Gilead Sciences
  • Abbott Laboratories
  • Heritage Pharmaceuticals
Market Segmentation

By Company Type

  • Tier 1 Pharmaceutical Companies
  • Tier 2 Pharmaceutical Companies
  • Tier 3 Pharmaceutical Companies

By Route of Administration

  • Inhalational
  • Intravenous

By End-Use

  • Hospitals
  • Ambulatory Surgery Centers

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Premature ejaculation is a type of sexual dysfunction…
Irritable bowel syndrome (IBS) is a group of…
The H1N1 flu (swine flu) is primarily caused…